跳至主要内容
临床试验/IRCT20230415057912N1
IRCT20230415057912N1招募中3 期

efficacy and safety of adding oral pioglitazone to standard treatment in lichen planopilaris

Esfahan University of Medical Sciences0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 50 years(—)
性别
All

入选标准

  • a disease that is resistant to treatment. It means that the treatment has been ineffective for at least 6 months.
  • Newly diagnosed patients who have not yet received treatment.
  • Patients who have been treated before and whose disease is still active.
  • Patients who, for any reason, have discontinued any previous medication 1 month before entering the study and have not used any other medication at the time of the study.
  • Patients between 18 and 50 years old

排除标准

  • Pregnancy or breastfeeding
  • platelet<100000
  • hemoglobin<9
  • Liver enzymes that are too normal for reference and active liver disease
  • Positive tests for viral hepatitis
  • Heart failure
  • Type 1 diabetes
  • Allergy to pioglitazone and methotrexate
  • Bladder cancer
  • Tissue edema

研究者

相似试验